Rituximab in refractory Wegener's granulomatosis: Favorable or not?

Am J Respir Crit Care Med. 2006 Apr 1;173(7):815-6; author reply 816. doi: 10.1164/ajrccm.173.7.815a.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Follow-Up Studies
  • Granulomatosis with Polyangiitis / drug therapy*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Prospective Studies
  • Remission Induction
  • Rituximab
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab